PRESS RELEASE Bloomberg (THEON:NA) / Reuters (THEON.AS)3 November 2025 – Theon International Plc (THEON) publishes its Q3 2025 Trading Update, along with its FY 2026 Revenue Target. Today, THEON increases FY 2025 revenue guidance to €435-445 million, higher than the initial guidance range of €410-430 million. Also, for the first time, THEON presents a revenue target for FY 2026, with revenue in the range of €570-590 million. The company targets at least 20% organic growth, with total growth of c.30% when factoring in the announced acquisition of Kappa Optronics. Financial Summary  9m 2025 9m 2024 ChangeOrder intake €232.7 m €121.0 m +92.3%Revenue €279.3 m €222.6 m +25.5%Adjusted EBIT1 €69.4 m €52.3 m +32.8%Adjusted EBIT margin1 24.8% 23.5% +1.3 p.p.Earnings per share €0.70 €0.56 +25.0%Capex €12.5 m €11.5 m +8.8%  Sep...

PUBLICATION OF ATRANSPARENCY NOTIFICATION – ACKERMANS & VAN HAARENPursuant to article 14 of the law of 2 May 2007, Nextensa NV/SA announces that it has received a transparency notification dated 30 October 2025 from Ackermans & van Haaren NV/SA (having its registered offices at Begijnenvest 113, 2000 Antwerp, Belgium). Ackermans & van Haaren has notified that, following an acquisition of additional shares on 28 October 2025, its total number of voting rights in Nextensa increased to 80.31% of the voting rights. Based on this transparency notification, Nextensa understands that Ackermans & van Haaren holds 68.13% of the total number of shares (= financial participation) in Nextensa NV/SA on 28 October 2025.Content of the notification: REASON FOR THE NOTIFICATION: acquisition or disposal of voting securities...

Coface records year-to-date net income of €176.3m, of which €52.1m in Q3-25; annualised ROATE at 12% Paris, 3 November 2025 – 5.35 p.m.Turnover: €1,386.5m, up +1.8% at constant FX and perimeterTrade credit insurance premiums were up +1.1% at constant FX; client activity was up +2.1% In Q3-25, services grew strongly, up +10.7%, in line with the strategy of strengthening the service offering Client retention returned to a high level at 93.5%, close to the 2023 records (93.9%); pricing is down by -1.8%, in line with historical trends Business information continued to post double-digit growth (+14.5% at constant FX), with debt collection up +38.5% and factoring up +0.4%Net loss ratio at 39.6%, up 4.1 ppts; net combined ratio at 71.9%Gross loss ratio at 36.9%, up 4.0 ppts year-on-year, with stable opening year reserving and continued...

Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year GuidanceReports record revenue of $21.2 million for the third quarter of 2025, an increase of $2.9 million, or 16%, compared to the same period in 2024. Reports record GAAP diluted EPS of $0.43 and non-GAAP diluted EPS of $0.47 for the third quarter of 2025, which are increases of 8% and 9%, respectively, compared to the same period in 2024. Raises full-year guidance to revenue of $82.5 million to $83.5 million and GAAP diluted EPS to $1.68 to $1.72. Declares a regular quarterly cash dividend of $0.17 per share of common stock for the fourth quarter of 2025, payable on November 25, 2025.ORLANDO, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) — IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD) announced today its financial results for the...

Third quarter sales up 0.6% over last year driven by 4.4% increase in Infrastructure; Rail sales down 2.2%, with Global Friction Management and Total Track Monitoring up 9.0% and 135.1%, respectively Backlog1 of $247.4 million up 18.4% over last year driven by 58.2% increase in Rail; all Rail business units realized substantial backlog increases, with Rail Products up 59.9%, Global Friction Management up 28.7%, and Technology Services and Solutions up 77.7% driven by improved order rates in the UK Third quarter operating cash flow was $29.2 million; $26.4 million in Free Cash Flow1 drove Gross Leverage1 to 1.6x, down 0.6x during the quarter; $4.7 million deployed to repurchase 184,143 shares Revised 2025 guidance mid-points assume a 22% increase in Adjusted EBITDA1 versus last year on 2% sales growth; fourth quarter Adjusted EBITDA anticipated...

Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth AUVELITY® 3Q 2025 net product sales of $136.1 million, representing 69% year-over-year growth SUNOSI® 3Q 2025 net product revenue of $32.8 million, representing 35% year-over-year growth SYMBRAVO® 3Q 2025 net product sales of $2.1 million sNDA for AXS-05 in Alzheimer’s disease agitation submitted to the FDA Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the third quarter of 2025 and provided a general business update. “Axsome posted strong revenue growth in the third quarter driven by contributions from...

–  Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the fourth quarter of 2025 –  Clinical update to focus on preliminary data from Phase 1 monotherapy dose expansion study of MICVO in 2L/3L R/M HNSCC patients, including from both post platinum & PD-1 and post EGFR & PD-1 arms, and preliminary data from Phase 1/2 combination dose escalation study of MICVO and KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC patients –  Presented translational data at ESMO 2025 and AACR-NCI-EORTC providing meaningful insights into MICVO’s first-in-concept non-cellular targeting antibody drug conjugate (ADC) mechanism of action –  Expected cash runway through data milestones and into...

Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million Raises full year 2025 global revenue target to $600 million, and raises full year BRIUMVI U.S. net revenue target to approximately $585 million Conference call to be held today, Monday, November 3, 2025, at 8:30 AM ET    NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2025, along with recent company developments, and provided an update on 2025 revenue guidance. Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, stated, “We are pleased to see that the third quarter marked another strong period of performance across our strategic priorities, driving continued BRIUMVI growth,...

—Q3 2025 ORLADEYO net revenue of $159.1 million (+37 percent y-o-y)—  —Q3 2025 operating profit of $29.6 million (+285 percent y-o-y); non-GAAP operating profit of $51.7 million (+107 percent y-o-y); continued improvement in non-GAAP operating profit margin from strong operating leverage— —ORLADEYO FY 2025 revenue guidance raised to between $590 to $600 million; FY 2025 non-GAAP operating expense guidance lowered to between $430 to $440 million— —Sale of European ORLADEYO business completed; proceeds used to retire all remaining Pharmakon term debt— —Definitive agreement signed to acquire Astria Therapeutics; transaction expected to close Q1 2026— RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the third quarter ended September 30,...

LONDON, Nov. 03, 2025 (GLOBE NEWSWIRE) — ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility tech provider, today announced unaudited financial results for the quarter ended September 30, 2025. Ziyu Shen, ECARX Chairman and CEO, commented, “The strong momentum from the first half of the year carried through into Q3, delivering several significant milestones that are reinforcing the sustainable foundation we are building for future growth. Most notably, we achieved EBITDA breakeven per our guidance in Q2, generating $8.3 million in Adjusted EBITDA and turned a profit for the first time with $0.9 million in net profit. Our focus on globalizing our business over the past three years is clearly yielding significant progress. The continuous expansion of our shipment volumes, enhanced supply chain efficiency...